NFE2L2 and metabolic disease: Although nuclear factor erythroid-related factor 2 (Nrf2) was suggested as a target of SFA to explain its antidiabetic effects [22], recent evidence suggested that SFA might have additional actions relevant to metabolic diseases [23,24].